Blueline Advisors »

Crispr Therapeutics shares owned by Blueline Advisors

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Blueline Advisors from 13F filings

Historical chart of Blueline Advisors investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Blueline Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Blueline Advisors

Quarter filed Position value Share count Share price at filing
2026-03-31 $952 20 47.60

More positions owned by Blueline Advisors

Vanguard Index Fds Value Etf (VTV)
Vanguard Index Fds Growth Etf (VUG)
Wisdomtree Tr Emg Mkts Smcap (DGS)
Ssga Active Etf Tr State Street Bla (SRLN)
Ishares Tr Eafe Sml Cp Etf (SCZ)
Invesco Exch Traded Fd Tr Ii Bloomberg Enhanc (PHB)
Vanguard Scottsdale Fds Int-term Corp (VCIT)
Vanguard Scottsdale Fds Shrt Trm Corp Bd (VCSH)
Ishares Tr Rus 2000 Val Etf (IWN)
Tortoise Capital Series Trus North Amrcn Pipe (TPYP)
Select Sector Spdr Tr State Street Uti (XLU)
Legg Mason Etf Invt Franklin Intl Lw (LVHI)
Ishares Tr Us Treas Bd Etf (GOVT)
Ishares Jp Mrgn Em Hi Bd (EMHY)
Vanguard Index Fds Real Estate Etf (VNQ)

View all positions for Blueline Advisors

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Orbis Allan Gray
Capital Research and Management Company - Division 3
State Street Corporation
T. Rowe Price Investment Management
UBS Group
Vanguard Group
Geode Capital Management
Susquehanna International
Sr One Capital Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
FMR
Citadel Advisors

View all funds holding Crispr Therapeutics